Abstract:The management of patients with inhibitory antibodies against factor VIII or FIX remains one of the most challenging aspects of modern hemophilia care. Control of bleeding in patients with high‐titer inhibitors often relies on the use of bypassing agents such as activated prothrombin complex concentrates or recombinant FVIIa (rFVIIa). The mechanism of action of pharmacologically dosed rFVIIa has been contentious 1.Margaritis P. Does rFVIIa work solo in hemophilia?.Blood. 2014; 123: 1631-3Crossref Scopus (2) Google Scholar. Unlike endogenous FVIIa, which binds to tissue factor (TF) at sites of vascular injury to promote the activation of FX and FIX, high‐dose rFVIIa appears to function via TF‐independent activation of FX on the surfaces of activated platelets 2.Feng D. Whinna H. Monroe D. Stafford D.W. FVIIa as used pharmacologically is not TF dependent in hemophilia B mice.Blood. 2014; 123: 1764-6Crossref PubMed Scopus (27) Google Scholar, 3.Keshava S. Sundaram J. Rajulapati A. Pendurthi U.R. Rao L.V. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody‐induced hemophilia mice.J Thromb Haemost. 2016; 14: 546-50Crossref PubMed Scopus (19) Google Scholar. The TF‐independent mechanism is supported by clinical findings with the rFVIIa analog FVIIa‐DVQ (also known as vatreptacog alfa). As compared with rFVIIa, FVIIa‐DVQ has enhanced TF‐independent activity 4.Allen G.A. Persson E. Campbell R.A. Ezban M. Hedner U. Wolberg A.S. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia.Arterioscler Thromb Vasc Biol. 2007; 27: 683-9Crossref PubMed Scopus (68) Google Scholar, improved hemostatic effects in hemophilic mouse models 5.Tranholm M. Kristensen K. Kristensen A.T. Pyke C. Rojkjaer R. Persson E. Improved hemostasis with superactive analogs of factor VIIa in a mouse model of hemophilia A.Blood. 2003; 102: 3615-20Crossref PubMed Scopus (95) Google Scholar, and superior efficacy in controlling bleeding episodes in hemophilic patients with inhibitors 6.Lentz S.R. Ehrenforth S. Karim F.A. Matsushita T. Weldingh K.N. Windyga J. Mahlangu J.N. Adept I. Recombinant factor VIIa analog in the management of hemophilia with inhibitors: results from a multicenter, randomized, controlled trial of vatreptacog alfa.J Thromb Haemost. 2014; 12: 1244-53Crossref PubMed Scopus (57) Google Scholar. Unfortunately, the clinical development of vatreptacog alfa was discontinued because of the development of anti‐drug antibodies 7.Mahlangu J.N. Weldingh K.N. Lentz S.R. Kaicker S. Karim F.A. Matsushita T. Recht M. Tomczak W. Windyga J. Ehrenforth S. Knobe K. Adept I. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.J Thromb Haemost. 2015; 13: 1989-98Crossref PubMed Scopus (43) Google Scholar. The nature of the rFVIIa‐binding site on activated platelets is obscure, but is presumed to comprise anionic phospholipids, because the γ‐carboxyglutamic acid (Gla) domain of rFVIIa is required 8.Hoffman M. Volovyk Z. Persson E. Gabriel D.A. Ezban M. Monroe D.M. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity.J Thromb Haemost. 2011; 9: 759-66Crossref PubMed Scopus (24) Google Scholar. The FVIIa Gla domain has a relatively low affinity for phospholipids, however, and platelet surface proteins have been proposed to support the binding and therapeutic activity of rFVIIa 9.Weeterings C. de Groot P.G. Adelmeijer J. Lisman T. The glycoprotein Ib‐IX‐V complex contributes to tissue factor‐independent thrombin generation by recombinant factor VIIa on the activated platelet surface.Blood. 2008; 112: 3227-33Crossref PubMed Scopus (67) Google Scholar. Interestingly, FVIIa‐DVQ binds to more sites per platelet than rFVIIa despite a similar extent of phospholipid binding, which raises the possibility that its higher therapeutic activity may be partly related to increased binding to an alternative site(s) on the platelet surface 8.Hoffman M. Volovyk Z. Persson E. Gabriel D.A. Ezban M. Monroe D.M. Platelet binding and activity of a factor VIIa variant with enhanced tissue factor independent activity.J Thromb Haemost. 2011; 9: 759-66Crossref PubMed Scopus (24) Google Scholar. In this issue of JTH, Fager et al. 10.Fager A.M. Machlus K.R. Ezban M. Hoffman M. Human platelets express endothelial protein C receptor which can be utilized to enhance localization of factor VIIa activity.J Thromb Haemost. 2018; 16: 1817-29Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar provide compelling evidence that one such site may be endothelial protein C receptor (EPCR). EPCR is a multifunctional cell surface protein that was initially discovered by Esmon et al. as a receptor for protein C and activated protein C (PCa) on endothelial cells 11.Fukudome K. Esmon C.T. Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor.J Biol Chem. 1994; 269: 26486-91Abstract Full Text PDF PubMed Google Scholar. It serves as a cofactor for protein C activation by the thrombin–thrombomodulin complex, and also as a coreceptor for protease‐activated receptor signaling 12.Pendurthi U.R. Rao L.V.M. Endothelial cell protein C receptor‐dependent signaling.Curr Opin Hematol. 2018; 25: 219-26Crossref PubMed Scopus (22) Google Scholar. EPCR is structurally homologous with class 1 major histocompatibility complex molecules. It contains a tightly bound phospholipid in its ‘antigen‐presenting groove’ that interacts directly with the Gla domain of protein C 13.Oganesyan V. Oganesyan N. Terzyan S. Qu D. Dauter Z. Esmon N.L. Esmon C.T. The crystal structure of the endothelial protein C receptor and a bound phospholipid.J Biol Chem. 2002; 277: 24851-4Abstract Full Text Full Text PDF PubMed Scopus (169) Google Scholar. FVIIa binds to EPCR with a similar affinity as protein C, probably also via its Gla domain 14.Mohan Rao L.V. Esmon C.T. Pendurthi U.R. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor.Blood. 2014; 124: 1553-62Crossref PubMed Scopus (135) Google Scholar. Despite its name, EPCR is not found only on the endothelium. It is known to be expressed at low levels on leukocytes, smooth muscle cells, keratinocytes, cardiomyocytes, and neurons 14.Mohan Rao L.V. Esmon C.T. Pendurthi U.R. Endothelial cell protein C receptor: a multiliganded and multifunctional receptor.Blood. 2014; 124: 1553-62Crossref PubMed Scopus (135) Google Scholar, 15.Zheng X. Li W. Song Y. Hu Y. Ferrell G.L. Esmon N.L. Esmon C.T. Non‐hematopoietic EPCR regulates the coagulation and inflammatory responses during endotoxemia.J Thromb Haemost. 2007; 5: 1394-400Crossref PubMed Scopus (45) Google Scholar. EPCR has not previously been demonstrated on platelets, although its mRNA has been detected by RNA sequencing 16.Rowley J.W. Oler A.J. Tolley N.D. Hunter B.N. Low E.N. Nix D.A. Yost C.C. Zimmerman G.A. Weyrich A.S. Genome‐wide RNA‐seq analysis of human and mouse platelet transcriptomes.Blood. 2011; 118: e101-11Crossref PubMed Scopus (419) Google Scholar. Fager et al. demonstrated that human platelets do indeed contain EPCR, that EPCR translocates to the cell surface upon platelet activation, and that the binding of rFVIIa or FVIIa‐DVQ to EPCR on activated platelets enhances the rate of activation of FX 10.Fager A.M. Machlus K.R. Ezban M. Hoffman M. Human platelets express endothelial protein C receptor which can be utilized to enhance localization of factor VIIa activity.J Thromb Haemost. 2018; 16: 1817-29Abstract Full Text Full Text PDF PubMed Scopus (9) Google Scholar. These findings suggest a model in which the Gla domain of rFVIIa interacts with the surfaces of activated platelets through two mechanisms: (i) direct binding to anionic phospholipids such as phosphatidylserine; and (ii) binding to the phospholipid‐containing antigen‐presenting groove of EPCR, which leads to more effective activation of FX (Fig. 1A). A limitation of the study by Fager et al. is that the relative contribution of EPCR to platelet‐dependent generation of FXa and thrombin was quite modest, accounting for only 20–30% of the total activity. It has been demonstrated previously that rFVIIa, in high concentrations, can compete with protein C for binding to EPCR on endothelial cells, resulting in inhibition of protein C activation 17.Pavani G. Ivanciu L. Faella A. Marcos‐Contreras O.A. Margaritis P. The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.Blood. 2014; 124: 1157-65Crossref PubMed Scopus (21) Google Scholar, 18.Sundaram J. Pendurthi U.R. Esmon C.T. Rao L.V. Blockade of endothelial cell protein C receptor augments factor VIIa hemostatic effect in hemophilia treatment.Blood. 2014; 124: 3031-3Crossref Scopus (12) Google Scholar (Fig. 1B). This mechanism also probably contributes to the therapeutic activity of rFVIIa by dampening the protein C anticoagulant system. Administration of anti‐EPCR antibodies augments the hemostatic effects of rFVIIa in hemophilia treatment 17.Pavani G. Ivanciu L. Faella A. Marcos‐Contreras O.A. Margaritis P. The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.Blood. 2014; 124: 1157-65Crossref PubMed Scopus (21) Google Scholar, 18.Sundaram J. Pendurthi U.R. Esmon C.T. Rao L.V. Blockade of endothelial cell protein C receptor augments factor VIIa hemostatic effect in hemophilia treatment.Blood. 2014; 124: 3031-3Crossref Scopus (12) Google Scholar, but it remains to be determined whether this is attributable to blockade of ECPR on platelets, endothelial cells, or both. The discovery of functional EPCR on platelets by Fager et al. has implications for the design of more effective rFVIIa therapeutics, perhaps by bioengineering variants with enhanced affinity for EPCR. This approach must be undertaken with caution, however, given the clinical experience with the rFVIIa variants vatreptacog alfa and BAY 86‐6150, which proved to be highly immunogenic in human subjects 7.Mahlangu J.N. Weldingh K.N. Lentz S.R. Kaicker S. Karim F.A. Matsushita T. Recht M. Tomczak W. Windyga J. Ehrenforth S. Knobe K. Adept I. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity.J Thromb Haemost. 2015; 13: 1989-98Crossref PubMed Scopus (43) Google Scholar, 19.Mahlangu J. Paz P. Hardtke M. Aswad F. Schroeder J. TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity.Haemophilia. 2016; 22: 873-9Crossref PubMed Scopus (21) Google Scholar. We are entering an exciting era in hemophilia care, with a plethora of therapeutic options on the horizon for the prevention and treatment of bleeding. Emerging therapies include extended‐half‐life FVIII and FIX products, gene therapy for hemophilia A and B, substitutive therapies such as the bispecific antibody emicizumab, and rebalancing therapeutics that target natural anticoagulants such as antithrombin, TF pathway inhibitor, or PCa. 20.Ling G. Nathwani A.C. Tuddenham E.G.D. Recent advances in developing specific therapies for haemophilia.Br J Haematol. 2018; 181: 161-72Crossref PubMed Scopus (26) Google Scholar. With this remarkable progress, what will be the future role of bypassing agents such as rFVIIa? Until the problem of inhibitor development in hemophilia is solved, the need for better bypassing agents is unlikely to disappear any time soon. S. X. Gu contributed to writing the manuscript and drafted the figure. S. R. Lentz wrote parts of the manuscript and revised the manuscript. Both authors approved the final version. S. R. Lentz has served as a paid consultant for Novo Nordisk and Opko. S. X. Gu states that he has no conflict of interest. This work was supported by the National Heart, Lung and Blood Institute (T32 HL007344 and R01 HL118742).National Heart, Lung, and Blood InstituteR01 HL118742T32 HL007344

High factor VIII concentrations interfere with glycoprotein VI-mediated platelet activation in vitro

Fibrin-glycoprotein VI interaction increases platelet procoagulant activity and impacts clot structure

Immobilized fibrinogen activates human platelets through glycoprotein VI

Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells

Characterization of interaction between blood coagulation factor VIII and LRP1 suggests dynamic binding by alternating complex contacts

Coagulation Factor XIIIa and Activated Protein C Activate Platelets via GPVI and PAR1

In-depth structure-function profiling of the complex formation between clotting factor VIII and heme

THE INTERACTION BETWEEN FACTOR VIII AND VON WILLEBRAND FACTOR

Binding of coagulation factor IXa to procoagulant platelets revisited: Low affinity and interactions with other factors

Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation

A critical role for the regulation of Syk from agglutination to aggregation in human platelets

Polymorphisms of glycoprotein Ib affect the inhibition by aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation

Control of Platelet Fibronectin Internalization and Cell Surface Retention by Fibrinogen: Lessons from Hypofibrinogemic Patients.

Targeting Platelet EPCR for Better Therapeutic Factor VIIa Activity

Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression

Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway

Endogenous factor VIII synthesis from the intron 22-inverted F8 locus may modulate the immunogenicity of replacement therapy for hemophilia A

Platelet-Derived Factor V Is a Critical Mediator of Arterial Thrombosis.

Two subpopulations of thrombin-activated platelets differ in their binding of the components of the intrinsic factor X-activating complex

Distinct platelet interactions with soluble and immobilized von Willebrand factor modulate platelet adhesion and aggregation with differential impact on hemostasis and thrombosis

Pharmacological Inhibition of Glycoprotein VI- and Integrin α2β1-Induced Thrombus Formation Modulated by the Collagen Type